Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...

Almost 2.4 million Americans wear continuous glucose monitors, or CGMs, to track their blood sugar—and not all of them have ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Its innovative CGM systems, like the G6 and the newer G7 ... G7 system and further development of offerings like the Dexcom Stelo, targeting non-insulin-using diabetes patients.

SAN DIEGO, August 26, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...